Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
August 20, 2020 02:02 PM EDTUpdated 02:58 PM
R&D
FDA+

No­var­tis gets the green light to start mar­ket­ing its next prospec­tive block­buster. And they're charg­ing a pre­mi­um for con­ve­nience

John Carroll

Editor & Founder

A last-minute holdup at the FDA has been cleared up as reg­u­la­tors stamped their ap­proval on No­var­tis’ new mul­ti­ple scle­ro­sis drug ofa­tu­mum­ab.

The FDA had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times